Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.

JSON

Tausch E, Ljungström V, Agathangelidis A, Zapatka M, Scarfò L, Jebaraj BMC, Yosifov DY, Müller A, Munugalavadla V, Degenhardt JD, Ghia P, Rosenquist R, Stilgenbauer S

Blood 139 (22) 3340-3344 [2022-06-02; online 2022-04-05]

Clinical Genomics Uppsala [Service]

PubMed 35377939

DOI 10.1182/blood.2021014550

Crossref 10.1182/blood.2021014550

pii: S0006-4971(22)00484-0